A Phase II Study of Pomalidomide, Daily Low Dose Oral Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Next Previous
Trial Profile

A Phase II Study of Pomalidomide, Daily Low Dose Oral Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 09 Jan 2017

At a glance

  • Drugs Pomalidomide (Primary) ; Cyclophosphamide; Dexamethasone
  • Indications Multiple myeloma
  • Focus Therapeutic Use

    • Most Recent Events

    • 05 Jan 2017 Planned End Date changed from 1 Dec 2016 to 1 Jun 2019.
    • 05 Jan 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Jun 2019.
    • 05 Jan 2017 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top